GCM Medical Group, PSC | San Juan, PR

Research site

(Unclaimed)

Location

Urb. Floral Park, #62 Calle Jose Marti, San Juan, Puerto Rico, United States of America

Site insights

Top conditions

Top treatments

Upadacitinib

Adalimumab

Risankizumab

ABT-494

Cenerimod

VX-147

BI 690517

Vicadrostat

Dupilumab

Nerandomilast

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 19 total trials

Locations recently updated

A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus (OPUS-2)

The goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematous in adult patients with moderate to sever...

Enrolling

Lupus Erythematosus, Systemic

Drug: Cenerimod

Drug: Placebo

Locations recently updated

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up)

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not...

Enrolling

Atopic Dermatitis

Drug: Upadacitinib Dose B

Drug: Upadacitinib Dose A

A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants

This study will evaluate the efficacy and safety of Armour Thyroid treatment compared with synthetic T4 in subjects who have primary hypothyroidism a...

Enrolling

Hypothyroidism

Drug: Levothyroxine

Drug: Armour Thyroid

A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO)

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent parti...

Active, not recruiting

Atopic Dermatitis

Drug: Rocatinlimab

Drug: Placebo

A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) (IMMpactful)

Psoriasis is a long-term skin disease which causes red, itchy, scaly patches most commonly on the knees, elbows, scalp, and torso (chest, back, and a...

Active, not recruiting

Moderate Plaque Psoriasis

Drug: Risankizumab

Drug: Deucravacitinib

Status recently updated

A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these cond...

Not yet enrolling

Enrolling

Hypertension

Cardiovascular Diseases

Drug: Placebo matching Vicadrostat

Drug: Vicadrostat

A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases

Adults 18 years of age and older or above legal age with lung fibrosis related to systemic autoimmune rheumatic disease can participate in this study...

Begins enrollment this month

Interstitial Lung Diseases

Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases

Drug: Nerandomilast

Drug: Placebo matching nerandomilast

Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus (OPUS OLE)

The goal of this clinical study is to learn about the long-term safety and tolerability of cenerimod in adult patients with moderate to severe sympto...

Invitation-only

Lupus Erythematosus, Systemic

Drug: Cenerimod

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease (AMPLITUDE)

The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants...

Enrolling

Proteinuric Kidney Disease

Drug: Placebo

Drug: VX-147